MAPT and Alzheimer disease: In fact, Sun et al. [11] identified that significantly decreased serum PF4 levels were positively correlated with cognitive decline and CSF biomarkers, including reduced Aβ40 and Aβ42, and negatively correlated with increased total tau proteins in Aβ-positive AD patients in a Chinese cohort, indicating that PF4 may become a promising anti-aging and therapeutic target for AD.